BrainStorm Cell Therapeutics Inc.BCLI
Neurology23 cited findings · profile updated 2026-08-25
1.00 USDnot live — refreshed daily
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. (BCLI) is focused on neurology. The company has completed a Phase 2 trial (NCT03799718) for MSC-NTF cells and a Phase 3 trial (NCT03280056) for NurOwn. NurOwn has received Orphan Drug designation in the U.S. and Europe.
The NurOwn Expanded Access Program (EAP) showed that 100% of patients exceeded 5-year survival, with an estimated mean survival of 84 months. The baseline ALSFRS-R in EAP patients was 41. The company is also conducting the NurOwn Phase 3b ENDURANCE study (NCT06973629), which has a planned enrollment of 200 participants. This study is a two-part trial consisting of a 24-week randomized, double-blind, placebo-controlled portion (Part A), followed by a 24-week open-label extension (Part B). The primary efficacy endpoint for Part A is the change from baseline to Week 24 on the ALSFRS-R.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| EAP patients exceeding 5-year survival | 100% for NurOwn Expanded Access Program (EAP) | BRAINSTORM CELL THERAPEUTICS INC. — SEC 8-K (2026-03-31), p.2 |
| Estimated mean survival in EAP cohort | 84 months for NurOwn Expanded Access Program (EAP) | BRAINSTORM CELL THERAPEUTICS INC. — SEC 8-K (2026-03-31), p.2 |
| Orphan Drug designation | received for NurOwn in U.S., Europe | BRAINSTORM CELL THERAPEUTICS INC. — SEC 8-K (2026-03-31), p.3 |
| Special Protocol Assessment (SPA) | granted for NurOwn (MSC-NTF) for ALS | BRAINSTORM CELL THERAPEUTICS INC. — SEC 8-K (2026-08-14), p.1 |
| Planned enrollment for NurOwn Phase 3b ENDURANCE study | 200 participants | BRAINSTORM CELL THERAPEUTICS INC. — SEC 8-K (2026-05-15), p.1 |
| Primary efficacy endpoint for NurOwn Phase 3b Part A | change from baseline to Week 24 on the ALSFRS-R | BRAINSTORM CELL THERAPEUTICS INC. — SEC 8-K (2026-03-31), p.1 |
Key projects
- NurOwn (ALS)
A completed Phase 3 trial (NCT03280056) for NurOwn.
- NurOwn (ALS) — U.S., Europe
NurOwn has received Orphan Drug designation in the U.S. and Europe.
- NurOwn Expanded Access Program (ALS)
100% of NurOwn Expanded Access Program (EAP) patients exceeded 5-year survival.
- NurOwn Phase 3b ENDURANCE study (ALS)
The NurOwn Phase 3b ENDURANCE study (NCT06973629) has a planned enrollment of 200 participants.
- MSC-NTF cells (progressive multiple sclerosis)
A Phase 2 open-label multicenter trial in progressive multiple sclerosis for MSC-NTF cells has been completed.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Neurology research library →